Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide ...

The following is a summary of “ER-α36 prevents high glucose-induced cellular senescence and apoptosis in renal tubular cell,” ...

Research shows that the drug tazemetostat – which is already approved for use in patients with one type of B-cell lymphoma – ...

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

August, a young man arrived at a busy hospital in Toronto, Canada , displaying what doctors later described as 'bizarre' ...

Comprehensive Market Analysis Highlights Growing Clinical Relevance Across Various Diseases, Limited Clinical Applications in Oncology and Significant Market Potential Attracting New Entrants and ...

Ezh2 loss promotes RUNX1 mutant-induced MDS Given that RUNX1 mutations are identified in ~\n30% of MDS patients harbouring EZH2 loss-of-function mutations 1,18,23, we examined how Ezh2 loss and ...

A Cancer Gene Therapy study reveals that MEOX2 promotes lung cancer progression while SMARCB1 acts as a tumor suppressor, influencing EGFR expression and response to tyrosine kinase inhibitors.

Background: Enhancer of zeste homolog 2 (EZH2) configures a histone methyl transferase enzyme that mediates the epigenetic silencing of target genes. Its overexpression has been related to tumor ...